Clear Creek Independent School District (APRE)
NASDAQ (CM) NASDAQ (CM) Primary 
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Sell Stocks for January 19th
APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.
New Strong Sell Stocks for Jan. 14
APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.86 per share a year ago.
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.87 per share a year ago.
